Wedbush Issues Positive Forecast for Sana Biotechnology (NASDAQ:SANA) Stock Price

Sana Biotechnology (NASDAQ:SANA) had its price objective boosted by Wedbush from $5.00 to $6.00 in a report released on Friday morning,Benzinga reports. They currently have an outperform rating on the stock.

SANA has been the topic of a number of other reports. Citizens Jmp raised their target price on Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a research note on Thursday, October 30th. Citigroup reaffirmed an “outperform” rating on shares of Sana Biotechnology in a report on Thursday, October 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sana Biotechnology in a report on Wednesday, October 8th. JMP Securities set a $8.00 target price on shares of Sana Biotechnology in a report on Thursday, October 30th. Finally, HC Wainwright decreased their price objective on Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Friday. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.33.

Sana Biotechnology Stock Performance

NASDAQ SANA traded up $0.04 during mid-day trading on Friday, reaching $4.09. 5,461,342 shares of the stock were exchanged, compared to its average volume of 6,789,225. Sana Biotechnology has a 1-year low of $1.26 and a 1-year high of $7.30. The stock has a market capitalization of $972.63 million, a PE ratio of -4.22 and a beta of 1.94. The business’s fifty day simple moving average is $4.06 and its 200 day simple moving average is $3.34.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03. On average, analysts anticipate that Sana Biotechnology will post -1.16 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in shares of Sana Biotechnology by 19.9% in the 3rd quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock valued at $32,408,000 after acquiring an additional 1,517,474 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Sana Biotechnology by 180.8% during the third quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock valued at $7,581,000 after purchasing an additional 1,375,029 shares during the period. WJ Financial Advisors LLC bought a new stake in Sana Biotechnology in the third quarter valued at approximately $43,000. Lyell Wealth Management LP acquired a new stake in Sana Biotechnology in the third quarter worth $37,000. Finally, Profund Advisors LLC bought a new position in shares of Sana Biotechnology during the third quarter worth $205,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.